Arkema consensus shows cautious stance, shares under sector scrutiny

Chemicals group Arkema faces a cautious analyst consensus with a mix of Sell and Hold ratings, while peers such as BASF and Solvay frame the sector backdrop for the Paris-listed shares.

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 15:02.

Arkema (FR0010313833) sits in a mixed analyst landscape today, with its Paris-listed shares viewed more cautiously than some European chemical peers. The consensus view, tracked across major broker updates, has shifted toward Hold and Sell stances in recent months.

What analysts are signaling

Data compiled by MarketBeat for Arkema’s US-traded ADR under the ticker ARKAY shows eight Wall Street analysts currently covering the stock, with 2 Sell ratings, 5 Hold ratings and only 1 Buy rating. This mix points to a cautious stance rather than a clear bullish call on the group.

The same overview reports that the average 12-month price objective for Arkema ADRs is around 65 US dollars, implying only moderate upside from recent quotations. While individual broker names are not disclosed in that snapshot, the majority-neutral positioning contrasts with more upbeat consensus profiles seen at larger peers like BASF and Solvay in recent months, according to sector roundups on European chemicals from Reuters.

Position in the European chemicals sector

Arkema competes with established players such as BASF, Solvay and Covestro in specialty chemicals, adhesives and advanced materials, sectors that remain sensitive to global industrial production and energy prices. Recent Reuters sector commentary notes that European chemical producers have been managing softer demand in construction and consumer goods, while benefiting from relatively stable energy input costs compared with the 2022 spike.

The balance of Sell and Hold ratings on Arkema fits this environment of muted growth expectations and selective capital expenditure plans across the sector. For investors on Euronext Paris, where Arkema shares are traded in euros, the cautious consensus provides a reference point against which to compare the stock’s valuation versus regional peers tracked in European chemical indices.

How Arkema makes its money

Arkema generates revenue primarily from specialty chemicals and advanced materials, including adhesives, coating resins, fluorochemicals and high-performance polymers used in automotive, construction, packaging and electronics applications, as described in its corporate materials. Key product platforms include adhesives under the Bostik brand and a portfolio of bio-based materials targeting lower-carbon solutions.

Where the shares trade today

Arkema shares (FR0010313833) trade on Euronext Paris; a live-verified, time-stamped last price in euros was not reliably accessible at the time of this check, so no current quotation is stated here.

Key data on the Arkema shares

• Company: Arkema S.A.
• ISIN: FR0010313833
• WKN: 778 975
• Ticker: AKE
• Trading venue: Euronext Paris
• Sector / industry: Chemicals - Specialty / Advanced Materials
• Index membership: CAC Next 20 / SBF 120 (according to Euronext overviews)
• Next earnings date: not officially scheduled

This article is for informational purposes only and does not constitute investment advice, an offer or a solicitation to buy or sell any securities. All data is based on sources considered reliable but cannot be guaranteed. Investors should conduct their own research or consult a qualified financial adviser.